A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours-Reference-Cited by-同舟云学术

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours

Published:2009-03-12 Issue:2 Volume:64 Page:425-429
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Scott Edwina N.,Thomas Anne L.,Molife L. Rhoda,Ahmed Samreen,Blagden Sarah,Fong Peter C.,Kowal Kristin,McCoy Candice,Wiesinger Herbert,Steward Will,De Bono Johann

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-009-0968-y.pdf

Reference8 articles.

1. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770–1782

2. Benson C, White J, De Bono J et al (2007) A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96:29–37

3. Van Veldhuizen PJ, Faulkner JR, Lara PN et al (2005) A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109. Cancer Chemother Pharmacol 56:39–45

4. Folkman J (1971) Tumour angiogensis: therapeutic implications. N Engl J Med 285:1182–1186

5. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09

2. New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective**;Chemistry – A European Journal;2022-08-03

3. Synthesis, 99mTc-labeling, in-vivo study and in-silico investigation of 6-amino-5-[(bis-(2-hydroxy-ethyl)-amino]methyl]2-methyl pyrimidin-4-ol as a potential probe for tumor targeting;Journal of Radioanalytical and Nuclear Chemistry;2022-07-22

4. Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts;Journal of Medicinal Chemistry;2022-03-02

5. Targeting CDK9 for the Treatment of Glioblastoma;Cancers;2021-06-18